Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
14 hedge funds and large institutions have $845K invested in Immune Pharmaceuticals Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
272% more capital invested
Capital invested by funds: $227K → $845K (+$618K)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
27% more funds holding
Funds holding: 11 → 14 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$691K |
| 2 |
Goldman Sachs
New York
|
+$57.9K |
| 3 |
Renaissance Technologies
New York
|
+$56.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$52.7K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$50.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$79K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$140 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $584K | +$691K | +93,551 | +879% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $67K | +$52.7K | +7,140 | +143% |
|
|
3
Goldman Sachs
New York
| $44K | +$57.9K | +7,843 | New |
|
|
VKH
4
Virtu KCG Holdings
New York
| $43K | +$50.2K | +6,803 | +908% |
|
|
5
Renaissance Technologies
New York
| $43K | +$56.3K | +7,625 | New |
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $24K | +$32.1K | +4,341 | New |
|
7
UBS Group
Zurich,
Switzerland
| $18K | +$23.4K | +3,172 | New |
|
|
TSS
8
Two Sigma Securities
New York
| $9K | +$11.6K | +1,575 | New |
|
|
EEG
9
E.E. Geduld
| $7K | – | – | – |
|
|
IFS
10
Ifrah Financial Services
Little Rock,
Arkansas
| $4K | – | – | – |
|
|
BFA
11
BlackRock Fund Advisors
San Francisco,
California
| $2K | +$281 | +38 | +13% |
|
|
SCM
12
Sio Capital Management
New York
| – | -$79K | -9,883 | Closed |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$140 | -19 | -90% |
|
|
LTFS
14
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$369 | +50 | +100% |
|
IMNP Hedge Fund Activity: Q3 2016 in Review
14 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q3 2016, worth a combined $845K — up 272% from $227K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IMNP positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $691K. The largest seller was Sio Capital Management, exiting entirely with an estimated $79K sold.
- 14 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q3 2016, up from 11 in Q2 2016.
- Funds reported $845K of Immune Pharmaceuticals Inc. stock for Q3 2016, up 272% quarter-over-quarter.
- 5 funds opened new Immune Pharmaceuticals Inc. positions in Q3 2016 and 2 closed out, a net change of +3 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q3 2016 was Vanguard Group, an estimated $691K added.
- The largest Immune Pharmaceuticals Inc. seller in Q3 2016 was Sio Capital Management, an estimated $79K sold.
Based on aggregated 13F filings for Q3 2016.